Cancer drug company Oncternal takes reverse merger route to stock market

Cancer drug developer Oncternal Therapeutics will become publicly traded, under terms of a reverse merger announced Thursday.

The San Diego company said it has agreed to purchase the majority ownership of GTx, a publicly traded biotech in Memphis, Tenn.

The merged company will also be named Oncternal…